456R-3

IDH1 R132H (MRQ-67) Rabbit Monoclonal Antibody

• Synonym(s): Isocitrate dehydrogenase 1
• UNSPSC Code: 12352203

Properties

• biological source: rabbit
• Quality Level: 100; 500
• conjugate: unconjugated
• antibody form: culture supernatant
• antibody product type: primary antibodies
• clone: MRQ-67, monoclonal
• description: For In Vitro Diagnostic Use in Select Regions
• form: buffered aqueous solution
• species reactivity: human
• packaging: vial of 0.1 mL concentrate (456R-34); vial of 0.1 mL concentrate, Research Use Only (456R-34-RUO); vial of 0.5 mL concentrate (456R-35); vial of 1.0 mL concentrate (456R-36); vial of 1.0 mL concentrate, Research Use Only (456R-36-RUO); vial of 1.0 mL pre-dilute ready-to-use (456R-37); vial of 1.0 mL pre-dilute, Research Use Only (456R-37-RUO); vial of 7.0 mL pre-dilute ready-to-use (456R-38); vial of 7.0 mL pre-dilute, ready-to-use, Research Use Only (456R-38-RUO)
• manufacturer/tradename: Cell Marque^™
• technique(s): immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100 (concentrated)
• isotype: IgG
• control: acute myeloid leukemia, astrocytoma, glioblastoma, oligodendroglioma
• shipped in: wet ice
• storage temp.: 2-8°C
• visualization: cytoplasmic
• Gene Information: human ... IDH1(3417)

Description

General description

Isocitrate dehydrogenase 1 (IDH1) functions as an enzyme in the Krebs (citric acid) cycle and is biologically active in the cytoplasmic and peroxisomal compartments under normal conditions. The occurrence of heterozygous missense mutations at an arginine residue at codon 132 (R132) within the coding region for the substrate binding site of IDH1 has been described to promote oncogenesis in several malignancies. Of the identified mutant variants, a histidine substitution (R132H) is one of the more frequently observed point mutations in certain tumor groups of gliomas. Mutations involving IDH1 have been implicated as early events during gliomagenesis and IDH1 mutation status was incorporated into the 2016 WHO Classification of Tumors of the Central Nervous System as a new parameter for sub-classifying diffuse astrocytic and oligodendrogliomal tumors.^3,4 Immunohistochemical identification of IDH1 R132H immunoreactivity can be used as a tool in screening tumors that may be harboring this mutation, such as low grade diffuse and anaplastic astrocytomas, oligodendrogliomas, and secondary glioblastomas.

Quality

United States - IVD
Canada - RUO
European Union - IVD
Japan - RUO

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Preparation Note

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Safety Information

• Storage Class Code: 12 - Non Combustible Liquids
• WGK: WGK 2
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable